Head and Neck Neoplasms
Conditions
Keywords
Head and Neck, Squamous Cell Carcinoma, Immune Checkpoint Inhibitors, Chemoradiation
Brief summary
The goal of this study is to determine the efficacy and safety of camrelizumab given concomitantly with chemoradiation in participants with unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). All participants will receive camrelizumab in addition to chemoradiation, the standard treatment for LA-HNSCC.
Interventions
DRUGCisplatin
75-100 mg/m\^2 administered as an IV infusion Q3W, for a total of 3 doses, at the same time as radiation: Day 1, Day 22, Day 43 of radiation.
RADIATIONIMRT or VMAT
66-70 Gy given in 33-35 fractions over 6-7 weeks.
BIOLOGICALCamrelizumab
Administered as an intravenous (IV) infusion every 2 weeks (Q2W): 14 days prior to radiation, then Day 1 of radiation and then every 14 days for total 8 doses.
Sponsors
West China Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent * Has a pathologically proven new diagnosis of head and neck squamous cell carcinoma * Has unresectable disease and is eligible for definitive chemoradiation based on investigator decision * Has Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) based on RECIST version 1.1 * Has adequate organ function as defined * Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy * Female and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to 180 days after the last dose of study therapy
Exclusion criteria
* Has cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer * Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study therapy * Has history of a diagnosed and/or treated hematologic or primary solid tumor malignancy, unless in remission for at least 5 years prior to randomization * Has a history of severe hypersensitivity reaction to camrelizumab, Cisplatin or radiotherapy * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study therapy * Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody or has previously participated in clinical studies with camrelizumab * Has received a live vaccine within 30 days prior to the first dose of study therapy * Has had prior systemic therapy, targeted therapy, radiotherapy treatment or radical surgery for head and neck cancer under study * Has not recovered from major surgery prior to starting study therapy * Has known active Hepatitis B or C * Has known history of Human Immunodeficiency Virus (HIV) * Has a significant cardiovascular disease * Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic treatment * Has had previous allogeneic tissue/solid organ transplant * Has active infection requiring systemic therapy * Is pregnant or breast feeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | 6 months | The number of participants with radiologically confrmed complete or partial response according to RECIST 1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 5 years | OS is the time from randomization to death due to any cause. |
| Disease-free Survival (DFS) | Up to 5 years | DFS is the time from the date of randomization to the date of first record of disease recurrence or death. |
| Acute Adverse Events (AEs) | Up to 6 months | The number of participants who experience unacceptable toxicity during protocol treatment as measured by the NCI CTCAE version 4.0 |
Contacts
Primary ContactYan Li, MD, PhD
Backup ContactXingchen Peng, MD,PhD
Outcome results
None listed